35Pharma to be acquired by GSK to accelerate development of HS235, a potential best-in-class investigational medicine for pulmonary hypertension (PH)
35Pharma to be acquired by GSK to accelerate development of HS235, a potential best-in-class investigational medicine for pulmonary hypertension (PH) is drawing significant interest across the industry.
35Pharma to be acquired by GSK to accelerate development of HS235, a potential best-in-class investigational medicine for pulmonary hypertension ...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Class 12 student ends life soon after writing exam
- LG reveals pricing for its 2026 OLED TVs
- India’s Sarvam launches Indus AI chat app as competition heats up
- Three quarters of London small business owners say work worries keep them awake at night
Source: Original →